Philip Kantoff
Vermögen: 1 377 $ am 31.08.2026
Vermögen: 1 377 $ am 31.08.2026
Philip Wayne Kantoff is the founder of Convergent Therapeutics, Inc. Current positions include Chairman-Global Treatment Science Network at Prostate Cancer Foundation, Independent Director at Context Therapeutics LLC since 2019, and Independent Director at Context Therapeutics, Inc. since 2018.
Former roles include Chairman-Medicine Department at Memorial Sloan Kettering Cancer Center, Director-Lake Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Inc. from 1989 to 2015, Director at Lank Center For Genitourinary Oncology, Independent Director at ESSA Pharma, Inc. from 2022 to 2025, Medicine Professor at Harvard University, Principal at National Institutes of Health, and Professor Emeritus-Medicine at Harvard Medical School.
Education includes a doctorate from Brown University conferred in 1979.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 24.06.2026 | 3 531 ( 0 % ) | 1 377 $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CONTEXT THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 01.12.2018 |
Context Therapeutics LLC
Context Therapeutics LLC Pharmaceuticals: MajorHealth Technology Manufactures hormone-responsive cancer drugs | Direktor/Vorstandsmitglied | 01.12.2019 |
Prostate Cancer Foundation
Prostate Cancer Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Corporate Officer/Principal | - |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapies for prostate cancer | Gründer | - |
| Unternehmen | Position | Ende |
|---|---|---|
| ESSA PHARMA INC. | Direktor/Vorstandsmitglied | 05.03.2025 |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Corporate Officer/Principal | 01.01.2015 |
Lank Center For Genitourinary Oncology | Direktor/Vorstandsmitglied | - |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Operates as a nonprofit cancer hospital | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 12 |
|---|---|
Brown University
Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Health Services |
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Operates as a nonprofit cancer hospital | Health Services |
National Institutes of Health
National Institutes of Health General GovernmentGovernment Engages in the improvement of health and saving lives | Government |
Prostate Cancer Foundation
Prostate Cancer Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ESSA Pharma, Inc.
ESSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs | Health Technology |
Context Therapeutics LLC
Context Therapeutics LLC Pharmaceuticals: MajorHealth Technology Manufactures hormone-responsive cancer drugs | Health Technology |
Context Therapeutics, Inc.
Context Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which develops treatment options for women living with hormone-dependent cancer | Health Technology |
Lank Center For Genitourinary Oncology | |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapies for prostate cancer | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen